Osteogenesis-promoting activity of composites SBA-15 mesoporous particles carrying oxytocin in vitro and in vivo.
This study analyzes the performance of SBA-15 mesoporous particles carrying oxytocin (OT) in promoting osteogenesis in vitro and in vivo. The SBA-15 particles synthesized in the previous studies (about 30 μm in diameter and containing 10 nm deep pores) were loaded with the drug oxytocin and cultured with human osteosarcoma MG-63 cell line in vitro. The influence of particles on cell proliferation was studied. The level of the osteogenic marker (alkaline phosphatase and type I collagen) was measured. For in vivo studies, the connectivity defects of rabbit skull were prepared, and SBA-15 suspensions were regularly injected at the defect sites. The changes in the defect site calcium salt deposition were measured, and morphological changes were observed by microscopy. The material had to promote effect on osteogenesis-related indicators such as alkaline phosphatase and collagen I in bone sarcoma cell line MG-63. In vivo, the calcium salt deposition in OT/SBA-15 group was significantly higher than in the blank group. SBA-15 carriers appeared to persist in the region of the defect after the injection and release the drugs slowly, thus playing a more distinct role in promoting bone repair of local bone defects. The results showed that SBA-15 particles with OT could slow the release drugs and could help in promoting osteogenesis.
Department of Prosthodontics, School of Stomatology, Jilin University, Changchun, China.
L
L
Cheng
Department of Prosthodontics, School of Stomatology, Jilin University, Changchun, China.
X
X
He
Department of Science and Education, School of Stomatology, Jilin University, Changchun, China.
Y
Y
Che
Department of Periodontics, School of Stomatology, Jilin University, Changchun, China.
H
H
Che
Department of Prosthodontics, School of Stomatology, Jilin University, Changchun, China.
M
M
Qian
D000469:Alkaline Phosphatase / Q000235:genetics / Q000378:metabolism; D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D002113:Calcification, Physiologic / Q000187:drug effects; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D024042:Collagen Type I / Q000235:genetics / Q000378:metabolism; D003692:Delayed-Action Preparations / Q000737:chemistry / Q000378:metabolism*; D004337:Drug Carriers / Q000737:chemistry / Q000378:metabolism*; D015870:Gene Expression; D006801:Humans; D010006:Osteoblasts / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D010012:Osteogenesis / Q000187:drug effects*; D010120:Oxytocics / Q000494:pharmacology*; D010121:Oxytocin / Q000494:pharmacology*; D010316:Particle Size; D011817:Rabbits; D012822:Silicon Dioxide / Q000737:chemistry / Q000378:metabolism*; D012886:Skull / Q000187:drug effects / Q000293:injuries / Q000378:metabolism
D015415:Biomarkers; D024042:Collagen Type I; D003692:Delayed-Action Preparations; D004337:Drug Carriers; D010120:Oxytocics; C509969:SBA-15; D010121:Oxytocin; D012822:Silicon Dioxide; D000469:Alkaline Phosphatase